



Feidhmeannacht na Seirbhíse Sláinte, Seirbhís Aisíocaíochta Cúraim Phríomhúil  
Bealach amach 5, M50, An Bóthar Thuaidh, Fionnghlas  
Baile Átha Cliath 11, D11 XKF3  
Fón: (01) 864 7100 Facs: (01) 834 3589

Health Service Executive, Primary Care Reimbursement Service  
Exit 5, M50, North Road, Finglas,  
Dublin 11, D11 XKF3  
Tel: (01) 864 7100 Fax: (01) 834 3589

Paul Murphy, T.D.  
Dáil Éireann,  
Leinster House,  
Kildare Street,  
Dublin 2.

23<sup>rd</sup> January 2025

PQ: 46423/25

**To ask the Minister for Health further to Parliamentary Question No. 1002 of 5 November 2024, given that Melatonin has not been reviewed since 2008, if he will instruct the NCPE to review and include this product for reimbursement under the Community Drugs Schemes; and if he will make a statement on the matter. -Paul Murphy**

Dear Deputy Murphy,

The Health Service Executive has been requested to reply directly to you in the context of the above Parliamentary Question (Reference 46423/24), which you submitted to the Minister for Health for response.

Medicines are added to the formal Reimbursement List following detailed assessments which include assessment of the clinical evidence, the economic evidence and the budget impact of a decision to reimburse specific indications of a medicine. The Primary Care Reimbursement Service is required to reimburse in line with approved decisions of the HSE and the HSE is required to formally assess each medicines and each specific use of such medicines before reimbursing them.

Pharmaceutical companies are required to submit and pricing and reimbursement application should they wish for their product to be added to the Reimbursement List.

Melatonin has never been available through the formal Reimbursement List for reimbursement under Community Drug Schemes. Under the Health (Pricing and Supply of Medical Goods) Act 2013, products that are licensed will undergo a pricing and reimbursement approval process by the National Centre for Pharmacoeconomics (NCPE) on receipt of an application by the HSE from the Marketing Authorisation Holder. Melatonin (Circadin®) underwent a review in 2008 and reimbursement was not recommended by the NCPE as there is currently insufficient evidence to support the reimbursement of this product under the Community Drugs Schemes (available at <http://www.ncpe.ie/drugs/melatonin-circadin/>).

The HSE Corporate Pharmaceutical Unit received an application for pricing and reimbursement of Melatonin (Slenyto® Prolonged-Release Tablets) in July 2019 from Flynn Pharma for the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient. The first step in the process is the submission of a rapid review dossier (a clinical and economic dossier) to the National Centre for Pharmacoeconomics (NCPE) for assessment. The rapid review was commissioned on 5th July 2022 and completed by the NCPE on 9th August 2022. The rapid review outcome recommends that a full Health Technology Assessment (HTA) is recommended to assess the clinical effectiveness and cost effectiveness of prolonged release melatonin (Slenyto®) compared to the current standard of care. However, to date the company have not made a HTA submission to the NCPE for assessment.

The position remains that a submission of a completed HTA dossier to the NCPE is required to progress this application, as per the formal processes governing the pricing and reimbursement of medicines.

The HSE Corporate Pharmaceutical Unit received an application for pricing and reimbursement of Melatonin (Voquily® 1mg/ml Oral solution) in September 2024 from Caragen Ltd for sleep onset insomnia in children and adolescents aged 6-17 years with attention-deficit hyperactivity disorder (ADHD) where sleep hygiene measures have been inadequate. The first step in the process is the submission of a rapid review dossier (a clinical and economic dossier) to the National Centre for Pharmacoeconomics (NCPE) for assessment. However, to date the company have not made a Rapid Review submission to the NCPE for assessment.

The position remains that a submission of a completed Rapid Review dossier to the NCPE is required to progress this application, as per the formal processes governing the pricing and reimbursement of medicines.

Yours sincerely,



Suzanne Doyle  
Primary Care Reimbursement Service

**The Health Service Executive operates the General Medical Services Scheme, which includes Medical Cards and GP Visit Cards, under the Health Act 1970, as amended. It has established a dedicated contact service for members of the Oireachtas specifically for queries relating to the status of Medical Cards and GP Visit Cards applications, which the Deputy / Senator may wish to use for an earlier response. Tel: 01-8647180 / email: [Oireachtas.pcrs@hse.ie](mailto:Oireachtas.pcrs@hse.ie)**